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Abstract
Purpose The paper presents a report on the comprehensive assessment of a novel synthetic opioid (NSO) termed U-47700, 
and its two metabolites: N-desmethyl-U-47700 and N,N-didesmethyl-U-47700 in autopsy blood samples taken from 12 
cases of fatal poisonings.
Methods The analysis of the examined samples was based on the solid-phase extraction/liquid chromatography–electrospray 
ionization-tandem mass spectrometry method, which was developed in the validation process. In the quantitative analytical 
studies, deuterium analytes analogs were used, namely U-47700-d6 and N-desmethyl-U-47700-d3.
Results The validation parameters of the method were determined, including the limits of quantification on the 1 ng/mL level, 
calibration curves range of 1–1000 ng/ml, intra-assay precisions and accuracies of 1.1–20.2% and −18.9–9%, respectively, 
and inter-assay precisions and accuracies of 2.9–13.0% and -11.4–3.3%, respectively. The matrix effects and the extraction 
efficiencies were formed at the levels of 54.0–119% and 53.0–118%, respectively. The parent substance and its metabolites in 
blood samples have been shown to be relatively stable under various conditions within the 21-day study. The concentration 
levels demonstrated in the analyzed blood samples were: U-47700 in the range of 83–24,000 ng/mL, N-desmethyl-U-47700 
in the range of 2.0–7520 ng/mL and N,N-didesmethyl-U-47700 in the range of 18–1947 ng/mL.
Conclusions The simultaneous quantification of U-47700, N-desmethyl-U-47700 and N,N-didesmethyl-U-47700 seems very 
useful to confirm the cause of death and to estimate antemortem interval. To our knowledge this is the first trial to measure 
phase I metabolites of U-47700 in authentic human blood samples.
Keywords Novel synthetic opioids · U-47700 · N-Desmethyl-U-47700 · N,N-Didesmethyl-U-47700 · Fatal intoxication · 
LC–MS/MS
Introduction
New psychoactive substances (NPS) are synthetic alterna-
tives to more traditional drugs of abuse, specifically engi-
neered to circumvent the existing drug control laws. The 
emergence of NPS is a global phenomenon fuelled by the 
growth of Internet commerce and manufacturing capacity 
of Asian countries [1]. As the recreational consumption of 
NPS has been increasing in Europe and in the world for the 
past decade, such compounds have proven to be quite a chal-
lenge for public health and drug policies globally [2]. By the 
end of 2017, the EMCDDA was monitoring more than 670 
NPS that had been identified in Europe [3]. While synthetic 
cathinones and cannabinoids continue to predominate, an 
increasing number of synthetic opioids including fentanyl 
derivatives and non-fentanyl analogs are more commonly 
encountered in the recreational (i.e., non-medical) drug mar-
ket in Europe and elsewhere [3, 4].
Novel synthetic opioids (NSOs) are progressively more 
often encountered in illicit heroin and counterfeit pain pills. 
Many NSOs are resurrected from older biomedical literature 
or patent applications, but limited information is available 
about their biological effects [1].
Recently, U-47700 [3,4-dichloro-N-[(1R,2R)-2-
(dimethylamino)-cyclohexyl]-N-methylbenzamide] has 
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been noted to appear on the drug of abuse market; its 
synthesis was patented by Szmuszkovicz in 1978 [5] as a 
result of studies that he carried out for the Upjohn Com-
pany. Preclinical studies determined that U-47700 was 
approximately 7.5 times more potent than morphine, but 
about 10 times less potent than fentanyl. The compound 
has not been studied in humans and no pharmacokinetic 
data are available [6, 7].
In 2016, Elliot et al. [8] were the first to describe a 
U-47700-associated death and to attempt probing into 
the problem of analytic differentiation between synthetic 
opioids U-47700 and AH-7921 that were mutual isobaric 
compounds. Since that time, the number of cases of intoxi-
cation being reported in the scientific literature concerning 
morbidity and mortality associated with U-47700 use has 
been consistently increasing [9].
In the qualitative and quantitative analysis of NSOs, 
including U-47700 and its metabolites, the method of 
liquid chromatography–(quadrupole) time-of-flight-mass 
spectrometry (LC–(Q)TOF-MS) and LC–ion trap  MSn 
technology were used [4, 10, 11]. According to Mohr 
et al. [12] and Gerace et al. [13], however, the LC–MS/
MS method provides a “golden standard” for quantitative 
analysis of NSOs in biological samples.
The present paper constitutes a report on the compre-
hensive assessment of a novel synthetic opioid U-47700 
and its two metabolites N-desmethyl-U-47700 and N,N-
didesmethyl-U-47700 in autopsy blood samples collected 
from 12 cases of poisonings involving U-47700. The eval-
uation of these compounds was preceded by development 
of the solid-phase extraction (SPE)/LC–electrospray ioni-
zation (ESI)-MS/MS method dedicated especially to such 
analysis, which had been subjected to a detailed validation 
process. The method included determination of significant 
validation parameters and the application of internal iso-
topically labeled standards in the form of U-47700-d6 and 
N-desmethyl-U-47700-d3.
Materials and methods
Biological materials
Samples of peripheral blood were collected from 12 
autopsy cases. The autopsies were carried out within 24 h 
after death. The samples were kept refrigerated (+4 °C) 
until the analyses were performed. Blank whole blood 
samples for development and validation of the analytical 
method were purchased from the Regional Blood Centre 
Donation in Kraków, Poland. Blank autopsy blood sam-
ples were also collected at the time of autopsy from non-
poisoned subjects.
Standards and chemicals
The standard solution of U-47700 (CRM) at the concentra-
tion of 1 mg/mL was obtained from Chiron (Trondheim, 
Norway); the standard solutions of N-desmethyl-U-47700 
(purity ≥98%), N,N-didesmethyl-U-47700 (purity ≥98), 
and U-47700-d6 (CRM) at the concentration of 1 mg/mL 
from Cayman Chemical (Ann Arbor, MI, USA); the stand-
ard solution of N-desmethyl-U-47700-d3 (CRM) at the 
concentration of 0.1 mg/mL from Cerriliant (Round Rock, 
TX, USA). Other common chemicals and solvents were pur-
chased from Sigma-Aldrich (Poznań, Poland).
Validation samples
For the calibrator samples, three working solutions in metha-
nol were prepared for constructing nine plots using the fol-
lowing concentrations: 0.1, 1 and 10 ng/μL of U-47700, 
N-desmethyl-U-47700 and N,N-didesmethyl-U-47700. 
Additionally, methanolic solutions were prepared for qual-
ity control (QC) samples at the concentrations of 1 and 
10 ng/μL for U-47700 and its metabolites. Calibrator and 
QC working solutions were made from different source lots. 
All the working solutions were stored at − 20 °C when not 
in use. Daily calibration samples were prepared by fortify-
ing 1 mL of blank blood with known amounts of U-47700 
and its metabolites at the concentrations ranging from 1 to 
1000 ng/mL.
Two QC specimens were also prepared daily at the con-
centrations of 25 and 250 ng/mL for U-47700 and its metab-
olites. For the deuterated internal standards (ISs), a working 
solution of 1 ng of U-47700-d6 and N-desmethyl-U-4700-d3/
μL in methanol was prepared and stored at − 20 °C, when 
not in use. Blank blood samples with and without ISs were 
prepared for evaluating peak purity.
Extraction
Each 1 mL sample was put into a clean 15 mL tube and 
diluted with 0.01 M carbonate buffer to pH 9.3 (1:5, 
v/v). One hundred microliters of IS working solution 
was added to each sample prior to extraction, producing 
a final deuterated IS concentration at 100 ng/mL. Subse-
quently, the samples were vortexed and centrifuged for 
7.5 min at 4400 × g. Bond Elut cartridge, filled with a 
non-polar bed of silica gel modified by octadecyl  (C18) 
reversed phase, with a weight of 500 mg was used (Agi-
lent, Santa Clara, CA, USA). The SPE cartridge was 
firstly equilibrated with 1 mL each of methanol, distilled 
water and the above carbonate buffer (pH 9.3), and then 
the supernatant of each blood sample was applied onto 
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the cartridge and slowly passed through it. In the next 
step, matrix impurities were cleaned with 2 mL of the 
carbonate buffer (pH 9.3), and then vacuum was applied 
to each cartridge for 30 min to remove residual moisture. 
The analytes were eluted with 2 mL of 1 M acetic acid 
in methanol (1:9, v/v). The eluate was evaporated to dry-
ness in a vacuum concentrator at 40 °C, and the residue 
was dissolved in 1 mL of the mixture of mobile phases 
(60% phase A + 40% phase B), and 10 µL was injected 
into the LC–MS system. The phase A was water, which 
contained 0.2% formic acid and 2 mM of ammonium for-
mate, and the phase B was acetonitrile with 0.2% for-
mic acid and 2 mM of ammonium formate. In the case 
of forensic blood samples, in which the concentrations 
of analytes exceeded the calibration ranges, the samples 
were adequately diluted with blank blood.
LC–ESI‑MS/MS method
An Agilent 1200 liquid chromatograph (Agilent) equipped 
with a binary pump (G1312 A) and an autosampler (G1329 
A) was used. The chromatographic separation was per-
formed with a Poroshell 120 C18 column (100 × 3 mm i.d., 
particle size 2,7 μm, Agilent). Chromatographic separation 
of U-47700 and its metabolites was performed under iso-
cratic conditions at the following composition of mobile 
phases: 60% A and 40% B at a flow rate of 0.5 mL/min. The 
total time of acquisition was 3 min. A 6410 triple quadrupole 
mass spectrometer (Agilent) with an ESI source, operated 
under a positive mode was used. The multiple reaction moni-
toring (MRM) detection was employed. The operational 
parameters of the ESI source were as follows: vaporizing 
temperature 350 °C; pressure of the nebulizing gas 40 psi; 
flow of the drying gas 9 L/min; capillary potential 3.5 kV. 
The fragmentation parameters of the analyzed compounds 
are listed in Table 1.
Validation of the SPE/LC–ESI‑MS/MS method
Selectivity and specificity
To evaluate the peak purity and selectivity, blank blood sam-
ples (no analyte or IS added) were analyzed with each batch 
to check for peaks that might interfere with the detection 
of U-47700 and its metabolites N-desmethyl-U-47700 and 
N,N-didesmethyl-U-47700. To assess possible interferences 
of other analytes (specificity), QC samples were spiked indi-
vidually to contain 1000 ng/mL of a mixture of about 400 
substances, including medicines, drugs of abuse, and NPS 
together with NSOs.
Linearity and limits of detection and quantification
The calibration curves were constructed after the analysis 
of drug-free blood containing known amounts of U-47700 
and its metabolites. To prepare these standards, blank blood 
samples were spiked with the compounds to the following 
concentrations: 1, 5, 10, 20, 50, 100, 200, 500 and 1000 ng/
mL for blood. Each level was prepared three times. The sam-
ples were extracted according to the procedure described 
above. The calibration curves were constructed by plotting 
the peak area ratios of the analyte U-47700 and N,N-dides-
methyl-U-47700/IS (U-47700-d6), N-desmethyl-U-47700/
IS (N-desmethyl-U-47700-d3). Negative QC samples were 
analyzed after each calibration sample to evaluate the poten-
tial carry-over. The limit of detection (LOD) of the method 
was determined by analyzing validation samples (n = 5) 
to determine if the acceptance criteria were met for each 
analyte. LOD was defined as the lowest concentration at 
which the analyte ion signal-to-noise ratio (determined by 
peak height) was ≥ 10, and chromatography (peak shape 
and resolution) and relative retention time (± 2% of target 
retention time) were acceptable. The limit of quantification 
(LOQ) was defined as the lowest concentration that met the 
Table 1  Fragmentation 
parameters for analytes and 
internal standards
Bold indicates quantitative ions
Compound Precursor 
ion (m/z)
Production (m/z) Fragmentor 
voltage (V)
Collision 
energy (V)
Retention 
time (min)
U-47700-d6 335.2 284.0 75 17 1.6
172.9 75 37
U-47700 329.1 284.1 60 13 1.6
173.0 60 37
N-Desmethyl-U-47700-d3 318.1 175.9 69 37 1.5
147.9 69 57
N-Desmethyl-U-47700 315.1 172.9 64 33 1.5
144.9 64 57
N,N-Didesmethyl-U-47700 301.1 270.0 65 13 1.4
172.9 65 33
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LOD criteria and had analyte quantification within ± 20% 
of the target value.
Accuracy and precision
Inter- and intra-assay accuracy and precision data for 
U-4700 and its metabolites were determined for each QC 
sample. Intra-assay data were obtained from one run (n = 3), 
and inter-assay data were determined among three separate 
runs (n = 9). Accuracy, expressed as a percentage, was cal-
culated by taking the difference between the mean measured 
concentration and reference concentration, dividing it by the 
reference concentration and multiplying by 100 for two QC 
concentrations (25 and 250 ng/mL). Precision, expressed as 
a percent relative standard deviation, was determined by cal-
culating the percent ratio of the standard deviation divided 
by the mean measured concentration ×100.
Extraction efficiency, matrix effect and process efficiency
Extraction efficiencies, matrix effects and process efficien-
cies were evaluated via three sets of samples (n = 5 for each 
set). Extraction efficiency for each analyte was measured at 
each QC concentration. Blank blood (five different lots) was 
fortified with reference standard solution before and after 
SPE. Percent extraction efficiency from blood was expressed 
as the mean analyte area of samples (n = 5) fortified with 
reference standard solution before extraction divided by 
the mean area of samples (n = 5) with reference standard 
solution added after SPE. Matrix effect was assessed by 
comparing the analyte peak areas in blank extracted blood 
specimens fortified with reference standard solutions after 
SPE with the peak areas of samples at the same nominal 
concentrations prepared in a 60:40 mixture of the mobile 
phase A and mobile phase B (neat sample). Matrix sup-
pression or enhancement was calculated as follows: [100 
× (mean peak area of fortified blood after SPE/mean peak 
area of neat sample)]. Process efficiency was examined for 
the overall effect of SPE extraction efficiency and matrix 
effect on the quantification of the analytes of interest. It was 
determined by comparing the mean analyte peak area of five 
samples fortified before SPE with the mean peak area of 
five neat samples prepared in the mobile phase at the same 
concentration.
Stability
The stability of U-47700 and its metabolites in the system 
of low QC blood samples was checked under the following 
conditions: − 30 °C, + 3 °C and ambient temperature (+ 
20 °C) in the 21-day study. The determinations of the ana-
lytes were carried out after 1, 7, 14 and 21 days of storage.
Results
In the first part of the work, to accurately quantify U-47700 
and its metabolites, a detailed procedure by SPE/LC–ESI-
MS/MS with the validation of the method was established.
At first, the specificity of the above method was tested by 
the use of more than about 400 compounds, such as medi-
cines, drugs of abuse and NPS including NSOs. None of 
them interfered with the peak of U-47700, its metabolites or 
IS. Even AH-7921, the isobaric compound of U-47700, did 
elute at another retention time. The selectivity experiment 
showed that all the blank blood samples were free of coelut-
ing peaks at the retention times of U-47700, its metabolites 
and their respective deuterated ISs. The analysis of the blank 
blood samples in each assay also demonstrated that the ISs 
did not contain relevant amounts of native U-47700 and its 
metabolites (Fig. 1a).
An overview of characteristic calibration data over a 
dynamic range from LOQs to 1000 ng/mL for U-47700 and 
its metabolites was done. A linear relationship between the 
concentration and peak area was obtained only for N,N-
desmethyl-U-47700. In case of U-47700 and N-desmethyl-
U-47700, the best fit of the trend line was obtained for the 
exponential and logarithmic function, respectively. All of the 
three curves were characterized by the coefficient of deter-
mination ≥0.999. The values of LODs, LOQs and the char-
acteristics of the calibration curves are shown in Table 2.
No detectable carry-over occurred following the 
1000 ng/mL U-47700 and its metabolites sample. Preci-
sion and accuracy of the method were evaluated at two 
concentrations within the dynamic range (25 and 250 ng/
mL). The data for both intra-assay (n = 3) and inter-assay 
(n = 9) are presented in Table 3.
The matrix effects for MRM quantification of the ana-
lytes and deuterated counterparts of ISs were practically 
on the identical levels. A similar relationship was observed 
for MRM qualification. The result of this phenomenon was 
a “mathematical abolition” of the matrix effects, which 
improved the precision and accuracy of the analytical 
methods. In the process of calibration, no commercially 
available deuterated IS of N,N-didesmethyl-U-47700 was 
used, which affected the deterioration of intra- and inter-
assay precision and accuracy. All the above data are shown 
in Table 4.
U-47700 and its metabolites in the QC blood samples 
were tested for the following conditions: − 30 °C, + 3 °C 
and +20 °C in the 21-day study. All of the analytes were 
characterized by high stability for 21 days even at 20 °C.
The results of toxicological findings of the examined 
samples are presented in Table 5. In Fig. 1b, the analytical 
data taken from Case no. 11 were selected to document the 
analytical procedure.
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Discussion
U-47700 as a synthetic opioid is a μ-receptor agonist, the 
action of which is manifested by a reduction in the sensation 
of pain and a reduction of emotions associated with pain, 
such as anxiety, fear and a sense of danger. The particularly 
dangerous side effects of opioid receptor agonists include 
the development of tolerance and addiction, and respiratory 
depression that can lead to death. Although U-47700 was 
synthesized at the end of the last century as an opioid anal-
gesic drug class in an attempt to develop a non-addicting 
analgesic, it has appeared only in recent years on the drug 
Fig. 1  Multiple reaction moni-
toring chromatograms obtained 
from the analysis of blank 
autopsy samples spiked with ISs 
(a) and Case no. 11 (b)
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market, gaining popularity among drug users as a legal 
alternative to heroin. U-47700 is available on the Internet 
in a powdered form which is usually taken through nasal 
inhalation or ingested in a capsule form. In 2016, U-47700 
was sought with a very high interest and was highly visible 
on the Internet, suggesting a new trend on the horizon for 
synthetic opioid abuse [14].
Toxicological findings of deaths associated with 
U-47700, which were the subject of the present study, orig-
inating from expert’s medico-legal opinions issued in the 
years 2016–2017, are shown in Table 5. The concentrations 
of the drug in the samples of blood were in a wide range 
of 83–24,000 ng/mL. In all the examined cases, apart from 
U-47700, other xenobiotics were detected, including alco-
hol in four instances, synthetic cannabinoids in four cases, 
medications in one case, phytocannabinoid, synthetic can-
nabinoids, synthetic cathinone and medications in one case, 
and synthetic cathinone and medications in two cases.
According to the published sources, the toxic effects 
of U–47700 in humans were demonstrated as overdos-
ing [15–17] and fatalities [12, 18–20]. In the cases of 
U-47700-related deaths, the concentration of the drug in 
autopsy blood samples was in the range of 59–525 ng/mL 
[12, 18, 19], and in the cases of fatal poisonings in multiple 
drug use, U-47700 concentration values in autopsy blood 
samples were in the range of 13.8–1460 ng/mL [8, 9].
As it follows from the analysis of fatal poisoning cases 
originating from the present study and other publications, 
the unpredictability of the toxic effect in cases of poisoning 
with one compound is possible; the said unpredictability 
may be the more strongly manifested in complex cases. 
Although no quantitative assessment of mutual relations 
based on casuistry is possible in cases of NPS taking, the 
governing principle is implying an intensified risk of their 
toxic effects [21, 22].
In the presently discussed cases, owing to employ-
ing the highly selective and sensitive method, apart from 
U-47700, the investigated blood samples showed the pres-
ence of N-desmethyl-U-47700 in the concentration range of 
2–7520 ng/mL and N,N-didesmethyl-U-47700 in the concen-
tration range of 18–1947 ng/mL. Their concentration values 
in the blood samples as compared to those of the precursor 
were variable, without showing a discernible trend. It could 
be also hypothetically assumed that they can demonstrate 
biological activites, similarly as desmethyl derivatives of 
numerous xenobiotics, which may significantly affect the 
toxicity of U-47700.
The U-47700 metabolism in the human body has never 
been the subject of detailed investigations; however, Krot-
ulski et al. [23] performed identification in vitro studies of 
U-47700 metabolites by LC–Q(TOF)-MS using human liver 
microsomes and confirmed the presence of four metabolites. 
Tracing the metabolic pathways of U-47700 indicated that 
N-desmethyl-U-47700 as the primary metabolite and N,N-
didesmethyl-U-47700 constitute products of demethylation 
of the parent substance at the nitrogen atom of the dimeth-
ylamino group of the cyclohexane ring, probably followed 
by forming hydroxylation products N-desmethyl-hydroxyl-
U-47700 and N,N-didesmethyl-hydroxyl-U-47700, respec-
tively (Fig. 2). Due to the fact that hydroxylation occurs 
Table 2  Calibration parameters
Compound Calibration curve Coefficient of  
determination (R2)
Limit of detection (LOD) 
[ng/ml]
Limit of  
quantification 
(LOQ) [ng/ml]
U-47700 y = 0.90077x1.05569 0.9997 0.5 1.0
N-Desmethyl-U-47700 y = − 0.02757x2 + 0.91125x  + 
0.00011
0.9998 0.5 1.0
N,N-Didesmethyl-U-47700 y = 0.24458x − 0.00004 0.9994 0.75 1.0
Table 3  Precision and accuracy 
data
RSD relative standars deviation
Compound Concentration 
in blood  
[ng/mL]
Intra-assay 
precision 
[%RSD]
(n = 3)
Intra-assay 
accuracy 
(%)
(n = 3)
Inter-assay 
precision 
[%RSD]
(n = 9)
Inter-assay 
accuracy 
(%)
(n = 9)
U-47700 25
250
1.6
1.1
− 3.9
7.3
2.9
4.7
− 0.9
1.7
N-Desmethyl-U-47700 25
250
1.4
1.2
− 4.7
9.0
3.3
4.3
− 1.1
3.3
N,N-Didesmethyl-U-47700 25
250
13.6
20.2
− 18.9
− 10.9
10.9
13.0
− 11.4
− 4.7
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within the cyclic ring and may happen in various positions 
of the ring, several positional isomers may be generated. The 
analysis of urine autopsy samples taken from five subjects 
confirmed the hypothetical metabolic profile with N-des-
methyl-U-47700 predominating. Unfortunately, the previous 
analyses of the metabolites in urine samples were qualitative 
and did not include blood samples [17, 23, 24].
Thus, in analyzes of blood autopsy samples collected 
from the victims of fatal poisonings presented in this arti-
cle, one can note confirmation of the metabolic profile of 
U-47700. The hypothetical metabolic profile of U-47700 is 
presented in Fig. 2.
Various investigators, including Kubo et al. [25] and 
Chung et al. [26], proved that fatal cases are an extremely 
valuable source of knowledge about trends in the use of vari-
ous drugs in individual countries around the world. Analyz-
ing the subject literature, the similarity in cross-section in 
NPS-related deaths discussed in this paper can be seen in 
the work of Kubo et al. [25], who presented the problem 
in a large research material covering 94 deaths. In most of 
reports published at the beginning of 2017, however, there 
were no deaths caused by synthetic opioids, which appeared 
in the world and also in Poland in the first half of the same 
year, and could be a novelty on the drug market.
In this article, we have quantified U-47700 and its two 
metabolites N-desmethyl-U-47700 and N,N-didesmethyl-
U-47700 in blood samples collected from 12 fatal poisoning 
victims. Being different from the concentrations of a xenobi-
otic and its metabolites, their concentrations seem to reflect 
toxicities being present at the time of cardiac arrest. This 
means that the values are very useful to confirm the cause 
of death and to estimate the antemortem-to-death interval. 
To our knowledge, this is the first trial to quantify phase I 
metabolites of U-47700 in authentic human blood samples.
Conclusions
We have presented, for the first time, a report on the com-
prehensive assessment of an NSO termed U-47700, and its 
two metabolites N-desmethyl-U-47700 and N,N-didesme-
thyl-U-47700 in autopsy blood samples collected from 12 
cases of fatal poisonings. For this purpose, we developed a 
sensitive and high-selective SPE/LC–ESI-MS/MS method in 
the validation process. The values quantified by the present 
method for U-47700 and its two metabolites in human blood 
samples seem very useful to confirm the cause of death and 
also to estimate the antemortem-to-death interval after con-
sumption of U-47700.
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Table 5  Results of toxicological analyses of U-47700, N-desmethyl-U-47700 and N,N-didesmethyl-U-47700 in authentic whole blood samples 
collected at autopsies
No. Case Analyte Concentra-
tion (ng/
mL)
Other (ng/mL)
1 Male, 24 years old
Found dead in his apartment
U-47700
N-Desmethyl-U-47700
N,N-Didesmethyl-U-47700
208
398
132
AB-CHMINACA (0.15)
2 Male, 26 years old
Found unconscious in his apartment, dead 
after ineffective resuscitation in hospital
U-47700
N-Desmethyl-U-47700
N,N-Didesmethyl-U-47700
1140
248
178
Bromazepam (100), trazodone (230), hydrox-
yzine (10), cetirizine (80), chlorprotixen 
(12), phenobarbital (1400)
3 Male, 16 years old
Admitted to hospital after school activities, 
dead after ineffective resuscitation
U-47700
N-Desmethyl-U-47700
N,N-Didesmethyl-U-47700
854
342
418
Hydroxyzine (20), cetirizine (60), 4-CMC (20)
4 Male, 24 years old
Found dead in his apartment
U- 47,700
N-Desmethyl-U-47700
N,N-Didesmethyl-U-47700
254
34
–
0.6 ‰ of ethyl alcohol
5 Male, 37 years old
Found dead near the shopping mall
U-47700
N-Desmethyl-U-47700
N,N-Didesmethyl-U-47700
779
184
317
0.7 ‰ of ethyl alcohol
6 Male, 25 years old
Found dead dead in his apartment
U-47700
N-Desmethyl-U-47700
N,N-Didesmethyl-U-47700
166
38
18
∆9-THC (1.6), THC–COOH (8), alpra-
zolam(92), 7-aminoclonazepam (22), nordi-
azepam (16), lamotrigine (2600), quetiapine 
(88), mianserin (180), paroxetine (230), 
N-ethylhexedrone (53), 5F-MDMB-PINACA 
O-desmethyl acid metabolite (0.40), AB-
FUBINACA O-desmethyl acid metabolite 
(2.30)
7 Male, 25 years old
Found dead on the sidewalk
U-47700
N-Desmethyl-U-47700
N,N-Didesmethyl-U-47700
24,000
7520
1250
1.8 ‰ of ethyl alcohol
8 Male, 58 years old
Admitted to hospital because of respiratory 
depression and cardiological problems, drugs 
abuse, dead after ineffective resuscitation
U-47700
N-Desmethyl-U-47700
N,N-Didesmethyl-U-47700
83
150
45
Tramadol (370), diazepam (37), nordiazepam 
(25), 7-aminoclonazepam (10), haloperidol 
(14), sertraline (27), propranolol (10), par-
acetamol (2800), PV8 (100)
9 Male, 35 years old
Found dead in the toilet at the gas station
U-47700
N-Desmethyl-U-47700
N,N-Didesmethyl-U-47700
204
2
–
2.9 ‰ of ethyl alcohol
10 Male, 39 years old
Drug dealer. Found dead in a bathtub in his 
apartment
U-47700
N-Desmethyl-U-47700
N,N-Didesmethyl-U-47700
83
260
1947
AB-FUBINACA O-desmethyl acid metabolite 
(2.44)
11 Male, 26 years old
He murdered his girlfriend with a knife and 
then committed suicide by drug overdose
U-47700
N-Desmethyl-U-47700
N,N-Didesmethyl-U-47700
1935
250
410
AB-FUBINACA O-desmethyl acid metabolite 
(110)
12 Female, 26 years old
She was murdered by her boyfriend with a 
knife
U-47700
N-Desmethyl-U-47700
N,N-Didesmethyl-U-47700
357
200
200
AB-FUBINACA O-desmethyl acid metabolite 
(196)
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